Low levels of IgM anticardiolipin antibodies in the first trimester were linked to microRNA changes resembling patterns seen in future pregnancy complications and increased cardiovascular risk.
Observational
Do low levels of IgM anticardiolipin antibodies in early pregnancy alter blood microRNA profiles compared to pregnancies without these antibodies?
Low levels of IgM anticardiolipin antibodies in early pregnancy are associated with microRNA changes that may indicate a slight increase in vulnerability to pregnancy complications or cardiovascular risk.
Some women have certain antibodies in their blood called anticardiolipin antibodies (aCL). These antibodies can sometimes be linked to pregnancy complications or a higher risk of heart disease. This study explored whether low levels of one type of these antibodies (called IgM aCL) early in pregnancy might still affect the body in ways that might matter later. We compared pregnant women with low levels of these antibodies to those without the antibodies and examined microRNAs-tiny molecules that help control cell activity-in their blood. Even low antibody levels were linked to small changes in microRNAs during the first trimester. Some of these changes resembled patterns seen in pregnancies that later develop complications or in people with increased cardiovascular risk. These findings do not mean that low antibody levels always cause problems. Instead, they suggest that such antibodies may slightly increase vulnerability, especially when combined with other risk factors.
Matraszek et al. (Thu,) conducted a observational in Pregnancy. Low IgM anticardiolipin antibodies vs. No IgM anticardiolipin antibodies was evaluated on MicroRNA profile changes. Low levels of IgM anticardiolipin antibodies in the first trimester were linked to microRNA changes resembling patterns seen in future pregnancy complications and increased cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: